Changes in the population of patients with dementia referred to Dementia disease centers in Japan as a result of the launch of Lecanemab

Abstract

Background: In Japan, Lecanemab could be administered to patients with early Alzheimer's disease in September 2023. Since the diagnosis of the disease would need to be made earlier than before, it was expected that patient referrals from primary care physicians to Dementia Disease Center specialists would increase.

The paper